Ventyx Biosciences Net Worth
Ventyx Biosciences Net Worth Breakdown | VTYX |
Ventyx Biosciences Net Worth Analysis
Ventyx Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Ventyx Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Ventyx Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Ventyx Biosciences' net worth analysis. One common approach is to calculate Ventyx Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Ventyx Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Ventyx Biosciences' net worth. This approach calculates the present value of Ventyx Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Ventyx Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Ventyx Biosciences' net worth. This involves comparing Ventyx Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Ventyx Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Ventyx Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ventyx Biosciences' net worth research are outlined below:
| Ventyx Biosciences generated a negative expected return over the last 90 days | |
| Ventyx Biosciences may become a speculative penny stock | |
| Ventyx Biosciences has high historical volatility and very poor performance | |
| Ventyx Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (192.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Ventyx Biosciences currently holds about 250.45 M in cash with (166.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.92, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 85.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 1651 shares by John Nuss of Ventyx Biosciences at 5.4034 subject to Rule 16b-3 |
Ventyx Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ventyx Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ventyx Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Ventyx Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ventyx Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ventyx Biosciences backward and forwards among themselves. Ventyx Biosciences' institutional investor refers to the entity that pools money to purchase Ventyx Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.3 M | Opaleye Management Inc | 2024-06-30 | 1.2 M | State Street Corp | 2024-06-30 | 1.2 M | Parkman Healthcare Partners Llc | 2024-06-30 | 1.2 M | Schonfeld Strategic Advisors Llc | 2024-06-30 | 1.2 M | Sphera Funds Management Ltd. | 2024-06-30 | 1 M | Jpmorgan Chase & Co | 2024-06-30 | 987.3 K | Sio Capital Management, Llc | 2024-06-30 | 778.9 K | Walleye Trading Advisors, Llc | 2024-06-30 | 510.8 K | Deerfield Management Co | 2024-06-30 | 5.8 M | Citadel Advisors Llc | 2024-06-30 | 5.8 M |
Follow Ventyx Biosciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 122.33 M.Market Cap |
|
Project Ventyx Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.69) | (0.73) | |
| Return On Capital Employed | (0.81) | (0.77) | |
| Return On Assets | (0.69) | (0.73) | |
| Return On Equity | (0.79) | (0.75) |
When accessing Ventyx Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Ventyx Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ventyx Biosciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Ventyx Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Ventyx Biosciences. Check Ventyx Biosciences' Beneish M Score to see the likelihood of Ventyx Biosciences' management manipulating its earnings.
Evaluate Ventyx Biosciences' management efficiency
Ventyx Biosciences has return on total asset (ROA) of (0.3339) % which means that it has lost $0.3339 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5424) %, meaning that it created substantial loss on money invested by shareholders. Ventyx Biosciences' management efficiency ratios could be used to measure how well Ventyx Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.73 in 2024. Return On Capital Employed is likely to rise to -0.77 in 2024. At this time, Ventyx Biosciences' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 18.2 M in 2024, whereas Total Assets are likely to drop slightly above 207.1 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.17 | 2.52 | |
| Tangible Book Value Per Share | 4.17 | 2.52 | |
| Enterprise Value Over EBITDA | (0.51) | (0.53) | |
| Price Book Value Ratio | 0.59 | 0.62 | |
| Enterprise Value Multiple | (0.51) | (0.53) | |
| Price Fair Value | 0.59 | 0.62 | |
| Enterprise Value | 1.5 B | 943.6 M |
The strategic vision of Ventyx Biosciences management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Return On Equity (0.54) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ventyx Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ventyx Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ventyx Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ventyx Biosciences time-series forecasting models is one of many Ventyx Biosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ventyx Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Ventyx Biosciences Earnings per Share Projection vs Actual
Ventyx Biosciences Corporate Management
| Matthew Moore | Chief Officer | Profile | |
| Sheila MD | Executive Chairperson | Profile | |
| John Nuss | Chief Officer | Profile | |
| Martin MD | Chief Officer | Profile | |
| Prof MD | Pres Officer | Profile | |
| MBA JD | Chief Officer | Profile |
Additional Tools for Ventyx Stock Analysis
When running Ventyx Biosciences' price analysis, check to measure Ventyx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventyx Biosciences is operating at the current time. Most of Ventyx Biosciences' value examination focuses on studying past and present price action to predict the probability of Ventyx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventyx Biosciences' price. Additionally, you may evaluate how the addition of Ventyx Biosciences to your portfolios can decrease your overall portfolio volatility.